Letters sent to healthcare professionals in October 2017

A letter was sent about injectable methylprednisolone products containing lactose (Solu-Medrone 40 mg); do not use in patients allergic to cow’s milk proteins.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 24 November 2017

• Therapeutic area: Paediatrics and neonatology and Respiratory disease and allergy

In October 2017, the following letter was sent to relevant healthcare professionals to inform them of updated safety information:

• Solu-Medrone 40 mg. Injectable methylprednisolone products containing lactose: new contraindication in patients allergic to cow’s milk proteins treated for allergic conditions

Article citation: Drug Safety Update volume 11, issue 4; November 2017: 7.

Published 24 November 2017